1. Activation of farnesoid X receptor downregulates visfatin and attenuates diabetic nephropathy. (5th January 2016) Authors: Zhou, Baoshang; Feng, Bing; Qin, Zhexue; Zhao, Youguang; Chen, Yu; Shi, Zhengmin; Gong, Yi; Zhang, Jing; Yuan, Fahuan; Mu, Jiao Journal: Molecular and cellular endocrinology Issue: Volume 419(2016) Page Start: 72 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Fibroblast growth factor 23 as a predictor of cardiovascular and all-cause mortality in prospective studies. (June 2017) Authors: Qin, Zhexue; Liu, Xi; Song, Mingbao; Zhou, Quan; Yu, Jie; Zhou, Baoshang; Wu, Yazhou; He, Yongming; Huang, Lan Journal: Atherosclerosis Issue: Volume 261(2017) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. The ubiquitin-activating enzyme E1 as a novel therapeutic target for the treatment of restenosis. (April 2016) Authors: Qin, Zhexue; Cui, Bin; Jin, Jun; Song, Mingbao; Zhou, Baoshang; Guo, Hongfeng; Qian, Dehui; He, Yongming; Huang, Lan Journal: Atherosclerosis Issue: Volume 247(2016) Page Start: 142 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. The ubiquitin-activating enzyme E1 as a novel therapeutic target for the treatment of restenosis. (April 2016) Authors: Qin, Zhexue; Cui, Bin; Jin, Jun; Song, Mingbao; Zhou, Baoshang; Guo, Hongfeng; Qian, Dehui; He, Yongming; Huang, Lan Journal: Atherosclerosis Issue: Volume 247(2016) Page Start: 142 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗